Investment Analysts’ Recent Ratings Changes for 4D Molecular Therapeutics (FDMT)

Several analysts have recently updated their ratings and price targets for 4D Molecular Therapeutics (NASDAQ: FDMT):

• 3/30/2026 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $21.00 price target on the stock, down from $40.00.
• 3/21/2026 – 4D Molecular Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/20/2026 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $36.00 price target on the stock.
• 3/19/2026 – 4D Molecular Therapeutics had its price target raised by Royal Bank Of Canada from $32.00 to $35.00. They now have an “outperform” rating on the stock.
• 3/19/2026 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.